Tirzepatide monotherapy in Chinese patients with early type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial (SURPASS-CN-MONO)

What Was Tested

The paper reports a study of Tirzepatide, published as a randomized controlled trial.

The researchers report findings from the Chinese SURPASS-CN-MONO trial (ClinicalTrials.gov: NCT05963022) of tirzepatide monotherapy.

Who Took Part

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and multicenter study.

Random assignment meant chance, not the researchers, decided who got Tirzepatide and who got the comparison, which limits bias.

As a double-blind Tirzepatide study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Tirzepatide could be set against what happens without it.

Running at several centres spread the Tirzepatide study over different clinics and patient groups.

A multicenter, randomized, double-blind, phase 3 trial conducted at 29 centers in China.

The primary endpoint was the mean change from baseline in hemoglobin A1c (HbA1c) at week 40.

What Was Measured

PubMed files the paper under topics including Tirzepatide, Diabetes Mellitus, Type 2, Glycated Hemoglobin, China, Hypoglycemic Agents, Blood Glucose and Hypoglycemia.

The authors tagged it with the keywords monotherapy, phase 3, translation to patients and type 2 diabetes.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Tirzepatide.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2026 (Med (New York, N.Y.)), a journal based in United States.

More context: the Tirzepatide compound page, all human trials.